Women's health: more HPV risk than expected

In the new survey, featuring women in their first relationship, 74% of respondents reportedly used barrier contraception. Yet nearly half developed some form of HPV infection. Companies such as Merck and Origenix, with vaccines in development for the virus, are likely to see significant revenues when their products hit the market.

Published By Datamonitor

Women's health: magnesium sulfate best for pre-eclampsia

Magnesium sulfate has long been used to treat of pre-eclampsia, but there has been a lack of statistically significant clinical trial evidence to support this. This means other drugs, including aspirin and Pfizer's Dilantin, have often been used instead. However, according to the new trial, magnesium sulfate is the most effective and cost-effective treatment option.

Published By Datamonitor

Women's health: contraceptives market is unattractive to investors

Published By Datamonitor

Women's health: changing the focus on clinical trials

The report draws attention to the problem of female underrepresentation in clinical trials. There is an ongoing debate regarding both the FDA's role in ensuring adequate representation of women within clinical trials, and in analyzing study results to ensure gender-related physiological differences are understood. The report should spur the FDA to increase its presence in these areas.

Published By Datamonitor

Wireless networking: Intel outside

Published By Datamonitor

Wireless LAN security: more holes than a Swiss cheese

Published By Datamonitor

Wireless gaming: US will see a dramatic rise

Published By Datamonitor

Will biotech companies take control in licensing deals?

Published By Datamonitor

Who will plug the brain metastases treatment gap?

One in 10 cancer patients fall foul of brain metastases - a patient population as large as that of lung or breast cancer. Despite this demand - and although many drugs have been shown to have activity in brain metastases - none are commonly used. This leaves a market with great unmet need and little competition - but who will fill the hole?

Published By Datamonitor

ViroPharma: cold cure may prove hard to justify

The common cold is certainly an attractive condition to target, considering its prevalence and its economic cost. However, Picovir's effect is to speeds the recovery rate, which is extremely hard to quantify in trials. As a result, it will be hard to justify its reimbursement. Preventative common cold drugs have a much greater potential.

Published By Datamonitor